OS Therapies is a mid-stage biotech company developing a Listeria-based immunotherapy, OST-HER2, for osteosarcoma. The company is financially constrained with $7.9 million in cash, relying on recent funding to sustain operations until 2026. The phase 2b trial is fully enrolled, with results expected in January 2025. While the therapy addresses an unmet need, past failures of similar treatments and uncertain funding pose risks.